According to the time Xu Zeming said, it is estimated that in late December, the country's major research institutes will be able to come up with the final results.

This is just in line with Zhang Chen's plan, otherwise there won't be so many Canaanite bacilli available now.

However, Zhang Chen emphasized to Xu Zeming that he would give priority to providing Canaanite to the single family.

After all, he had already promised Shan Zhemao about this.

When it comes to the military department, it goes without saying too clearly that the factories managed by a single family must have a close relationship with the state.

And after Xu Zeming heard this, he agreed without thinking about it.

It can be seen that the single family is indeed backed by the state.

ended the call with Xu Zeming.

Zhang Chen lay comfortably on his back in the chair, feeling relieved.

Since then, the bull cups that were bragged at the new product launch conference have been completed.

Now in the company, except for the oncolytic virus and two capsules, there are no other projects.

Although the production space is not enough, there are still many laboratories, and the R&D test can be continued.

Thinking of this, Zhang Chen felt that gene therapy drugs could continue to develop some other drugs.

Many companies are engaged in gene therapy research, but after so many years, there is still no gratifying progress.

From the perspective of adaptation symptoms, neurological diseases, metabolic diseases, ophthalmic diseases, and blood diseases are the main targets of adeno-associated virus gene therapy.

Most domestic companies are developing adeno-associated virus gene therapies, mainly for ophthalmic diseases and rare diseases.

Ophthalmic diseases, including retinopathy, macular degeneration, and color blindness.

These diseases are difficult to completely cure with ordinary treatments.

Gene therapy, on the other hand, is from the genetic level to completely solve the problems of these diseases.

In addition, rare diseases are more rare than ordinary diseases, as you can tell by their names.

But rare diseases are, in a way, not uncommon.

There are nearly 7,000 different types of rare diseases in China.

Under the huge population base in China and the wide variety of rare diseases, the number of rare disease patients has already exceeded 10 million, approaching the 20 million mark.

However, less than 10% of rare diseases have symptomatic treatments.

Such shocking figures are touching.

There is also a large number of unmet clinical needs for gene therapy in the field of rare diseases.

In addition, adeno-associated virus gene therapy also has a very strong therapeutic effect on other diseases.

For example, neurological diseases, hemophilia, spinal myeloid muscular atrophy, heart failure, Lieber's congenital amaurosis, Duchenne muscular dystrophy and arthritis.

It's all a choice of directions to overcome.

This therapy can even be effective for some cancers.

But with oncolytic viruses, there is no need to go through gene therapy.

Zhang Chenlai did not refuse, and directly simulated all the technical information related to all the diseases mentioned above.

All of them were sent to Tian Wenbin and Jiang Lu.

These two people have advantages and experience in the field of adeno-associated viruses that others cannot match.

Subsequently, Zhang Chen found Tian Wenbin and the two.

Tian Wenbin was already numb to the information that Zhang Chen took out.

He consciously chose to shut up, and didn't talk too much.

The three of them gathered in the office and discussed the approximate development sequence.

It was unanimously decided to solve a rare disease in a hurry, Krabbe disease, first.

This is a rare autosomal, recessively inherited neurodegenerative disease.

It is caused by loss-of-function mutations in the lysosomal enzyme galactosylceramide gene gene.

This loss of gene function leads to a class of lipids that accumulate in large numbers in cells.

This causes the death of myelin cells in the brain and peripheral nervous system, which in turn leads to the loss of some or all of the patient's motor function.

Sadly, infantile patients usually die before the age of 2 when they get the disease.

Some lucky late onseters can only survive until they are about 10 years old.

With the current level of medical care, there is no complete cure for this disease.

Once you suffer from this kind of disease, you can only wait for death in despair, but those who suffer from this disease are all children.

The reason why the three of them decided to develop this drug first is because Tian Wenbin has investigated before, and many such patient medical records have begun to appear in China in recent years.

He mentioned this to his previous boss as early as when Borui Biotech was around.

But it is conceivable that with Zhang Jingxin's greedy character, the market for this disease is too small, and he will definitely not agree to do it.

Seeing Tian Wenbin's research data, Zhang Chen didn't say a word, so he decided to solve this Krabbe disease first.

It won't take much time to fully develop this drug.

Since the mass spectrometer has been added, with this accurate detection method, the speed of research and development has been improved a lot.

With the current assembly line-like listing process, it is estimated that in less than a month and a half, those children who are sick will be able to recover completely.

After that, there are arthritis and eye diseases.

These two types of diseases are more common to older people.

Finally, there is spinal myeloid muscular atrophy and amaurosis.

At this stage, these two diseases are also in a state of incurable.

After finalizing the gene therapy project.

Zhang Chen went to learn about the capsule research and development project presided over by Pei Yuanxun.

Thinking quick capsule and physical energy fast-acting capsule are also items that Zhang Chen values more.

These two products can completely affect and even change the living conditions of all human beings.

When I asked, I found out that Mr. Pei had already made a lot of discoveries.

With his character, he planned to wait until the results were fully made before he would mention this matter to Zhang Chen.

In this regard, Zhang Chen couldn't cry or laugh.

He thought that the project had not made much progress.

But after looking at the data, he realized that the project was not slowing down.

It is estimated that in more than ten days, production can be arranged directly.

This time is just in time for the completion of the construction of the park.

Through the efforts of Mr. Bei's entire team, they even found that there is an infinite upper limit for these two products.

Mr. Pei felt that after the existing information was thoroughly studied, he could immediately try to develop a product with better results.

But what he didn't know was that the R&D data of the next generation of products was only a matter of minutes for Zhang Chen.

Now, oncolytic viruses have come up with a system.

As long as this system is completed, cancer can be completely conquered.

However, it will take some time to achieve.

Today, gene therapy has also sorted out a systematic research and development idea.

It can be continuously advanced to the later research and development, and there are at least hundreds of products that can be made.

For the Molecular Farm project, the R&D task is the heaviest.

All the drugs developed by these companies need to be integrated into crops or fruits by Academician Li Bozhan and his team.